The Effects of Tolterodine Extended Release and Alfuzosin for the Treatment of Double-J Stent―Related Symptoms
To evaluate the effects of tolterodine extended release (ER) and alfuzosin for the treatment of Double-J stent-related lower urinary tract symptoms. Fifty-two patients (33 men and 19 women; mean age 52.0 years) who underwent insertion of a Double-J stent after urological surgery were prospectively r...
Gespeichert in:
| Veröffentlicht in: | Journal of endourology 2009-11, Vol.23 (11), p.1913-1917 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1917 |
|---|---|
| container_issue | 11 |
| container_start_page | 1913 |
| container_title | Journal of endourology |
| container_volume | 23 |
| creator | Park, Seung Chol Jung, Sung Won Lee, Jea Whan Rim, Joung Sik |
| description | To evaluate the effects of tolterodine extended release (ER) and alfuzosin for the treatment of Double-J stent-related lower urinary tract symptoms.
Fifty-two patients (33 men and 19 women; mean age 52.0 years) who underwent insertion of a Double-J stent after urological surgery were prospectively randomized into three groups. Group 1 included 20 patients who received 10 mg of alfuzosin, once daily for 6 weeks; group 2 included 20 patients who received 4 mg of tolterodine ER, once daily for 6 weeks; group 3 included 12 patients who received a placebo for the same protocol. All patients completed a validated Ureteral Stent Symptom Questionnaire at 6 weeks after the stent placement.
The mean urinary symptom index was 22.1 in group 1, 22.1 in group 2, and 28.1 in the placebo group (p = 0.032). The mean pain scores were 8.2, 11.7, and 16.2, respectively (p = 0.020). There were no significant differences in urinary symptoms and pain between the alfuzosin and tolterodine ER groups. In addition, there was no significant difference in the general health, work performance, and sexual performance scores among the groups.
Tolterodine ER and alfuzosin improve stent-related urinary symptoms and body pain. |
| doi_str_mv | 10.1089/end.2009.0173 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_734126940</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A213589715</galeid><sourcerecordid>A213589715</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-3cfc4cbb6ddf7a628a9badb720a91da664f1cba07f8c1bc5f3aee4b37f1582c3</originalsourceid><addsrcrecordid>eNptkU2L1TAUhoMozp3RpVspiMyq16Rpm2Z5GccvBgacLtyF0-REK2lzTVJwXPkn_IPzSyblXhRhyCJw8jxvQl5CXjC6ZbSTb3A224pSuaVM8Edkw5pGlJLSL4_JJp9XpRCSnpDTGL9TynjL-FNywmTH6lbKDdn337C4tBZ1ioW3Re9dwuDNOOfxz5TT0RSf0SFELGA2xc7Z5ZeP41xYH4qU7T4gpAnntPpv_TI4LD8VN9lNd7__ZBdSzri5nfbJT_EZeWLBRXx-3M9I_-6yv_hQXl2__3ixuyo172Qquba61sPQGmMFtFUHcgAziIqCZAbatrZMD0CF7TQbdGM5INYDF5Y1XaX5GTk_xO6D_7FgTGoao0bnYEa_RCV4zapW1jSTrw7kV3Coxtn6FECvtNpVjDedFKzJ1PYBKi-D06j9jHbM8_-E8iDo4GMMaNU-jBOEW8WoWptT-W_V2pxam8v8y-ODl2FC848-VpWB10cAogZnA8x6jH-5Kl8tpZD8HlkIosU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734126940</pqid></control><display><type>article</type><title>The Effects of Tolterodine Extended Release and Alfuzosin for the Treatment of Double-J Stent―Related Symptoms</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Park, Seung Chol ; Jung, Sung Won ; Lee, Jea Whan ; Rim, Joung Sik</creator><creatorcontrib>Park, Seung Chol ; Jung, Sung Won ; Lee, Jea Whan ; Rim, Joung Sik</creatorcontrib><description>To evaluate the effects of tolterodine extended release (ER) and alfuzosin for the treatment of Double-J stent-related lower urinary tract symptoms.
Fifty-two patients (33 men and 19 women; mean age 52.0 years) who underwent insertion of a Double-J stent after urological surgery were prospectively randomized into three groups. Group 1 included 20 patients who received 10 mg of alfuzosin, once daily for 6 weeks; group 2 included 20 patients who received 4 mg of tolterodine ER, once daily for 6 weeks; group 3 included 12 patients who received a placebo for the same protocol. All patients completed a validated Ureteral Stent Symptom Questionnaire at 6 weeks after the stent placement.
The mean urinary symptom index was 22.1 in group 1, 22.1 in group 2, and 28.1 in the placebo group (p = 0.032). The mean pain scores were 8.2, 11.7, and 16.2, respectively (p = 0.020). There were no significant differences in urinary symptoms and pain between the alfuzosin and tolterodine ER groups. In addition, there was no significant difference in the general health, work performance, and sexual performance scores among the groups.
Tolterodine ER and alfuzosin improve stent-related urinary symptoms and body pain.</description><identifier>ISSN: 0892-7790</identifier><identifier>EISSN: 1557-900X</identifier><identifier>DOI: 10.1089/end.2009.0173</identifier><identifier>PMID: 19814699</identifier><language>eng</language><publisher>Larchmont, NY: Liebert</publisher><subject><![CDATA[Adolescent ; Adrenergic alpha-Antagonists - administration & dosage ; Adrenergic alpha-Antagonists - therapeutic use ; Adult ; Aged ; Aged, 80 and over ; Alfuzosin ; Benzhydryl Compounds - administration & dosage ; Benzhydryl Compounds - therapeutic use ; Biological and medical sciences ; Cresols - administration & dosage ; Cresols - therapeutic use ; Delayed-Action Preparations ; Demography ; Dosage and administration ; Drug therapy ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Muscarinic Antagonists - administration & dosage ; Muscarinic Antagonists - therapeutic use ; Nephrology. Urinary tract diseases ; Phenylpropanolamine - administration & dosage ; Phenylpropanolamine - therapeutic use ; Postoperative Complications - drug therapy ; Postoperative Complications - etiology ; Quinazolines - administration & dosage ; Quinazolines - therapeutic use ; Stents - adverse effects ; Surveys and Questionnaires ; Tolterodine Tartrate ; Urologic diseases ; Young Adult]]></subject><ispartof>Journal of endourology, 2009-11, Vol.23 (11), p.1913-1917</ispartof><rights>2009 INIST-CNRS</rights><rights>COPYRIGHT 2009 Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-3cfc4cbb6ddf7a628a9badb720a91da664f1cba07f8c1bc5f3aee4b37f1582c3</citedby><cites>FETCH-LOGICAL-c389t-3cfc4cbb6ddf7a628a9badb720a91da664f1cba07f8c1bc5f3aee4b37f1582c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22139979$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19814699$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Seung Chol</creatorcontrib><creatorcontrib>Jung, Sung Won</creatorcontrib><creatorcontrib>Lee, Jea Whan</creatorcontrib><creatorcontrib>Rim, Joung Sik</creatorcontrib><title>The Effects of Tolterodine Extended Release and Alfuzosin for the Treatment of Double-J Stent―Related Symptoms</title><title>Journal of endourology</title><addtitle>J Endourol</addtitle><description>To evaluate the effects of tolterodine extended release (ER) and alfuzosin for the treatment of Double-J stent-related lower urinary tract symptoms.
Fifty-two patients (33 men and 19 women; mean age 52.0 years) who underwent insertion of a Double-J stent after urological surgery were prospectively randomized into three groups. Group 1 included 20 patients who received 10 mg of alfuzosin, once daily for 6 weeks; group 2 included 20 patients who received 4 mg of tolterodine ER, once daily for 6 weeks; group 3 included 12 patients who received a placebo for the same protocol. All patients completed a validated Ureteral Stent Symptom Questionnaire at 6 weeks after the stent placement.
The mean urinary symptom index was 22.1 in group 1, 22.1 in group 2, and 28.1 in the placebo group (p = 0.032). The mean pain scores were 8.2, 11.7, and 16.2, respectively (p = 0.020). There were no significant differences in urinary symptoms and pain between the alfuzosin and tolterodine ER groups. In addition, there was no significant difference in the general health, work performance, and sexual performance scores among the groups.
Tolterodine ER and alfuzosin improve stent-related urinary symptoms and body pain.</description><subject>Adolescent</subject><subject>Adrenergic alpha-Antagonists - administration & dosage</subject><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alfuzosin</subject><subject>Benzhydryl Compounds - administration & dosage</subject><subject>Benzhydryl Compounds - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cresols - administration & dosage</subject><subject>Cresols - therapeutic use</subject><subject>Delayed-Action Preparations</subject><subject>Demography</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Muscarinic Antagonists - administration & dosage</subject><subject>Muscarinic Antagonists - therapeutic use</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Phenylpropanolamine - administration & dosage</subject><subject>Phenylpropanolamine - therapeutic use</subject><subject>Postoperative Complications - drug therapy</subject><subject>Postoperative Complications - etiology</subject><subject>Quinazolines - administration & dosage</subject><subject>Quinazolines - therapeutic use</subject><subject>Stents - adverse effects</subject><subject>Surveys and Questionnaires</subject><subject>Tolterodine Tartrate</subject><subject>Urologic diseases</subject><subject>Young Adult</subject><issn>0892-7790</issn><issn>1557-900X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU2L1TAUhoMozp3RpVspiMyq16Rpm2Z5GccvBgacLtyF0-REK2lzTVJwXPkn_IPzSyblXhRhyCJw8jxvQl5CXjC6ZbSTb3A224pSuaVM8Edkw5pGlJLSL4_JJp9XpRCSnpDTGL9TynjL-FNywmTH6lbKDdn337C4tBZ1ioW3Re9dwuDNOOfxz5TT0RSf0SFELGA2xc7Z5ZeP41xYH4qU7T4gpAnntPpv_TI4LD8VN9lNd7__ZBdSzri5nfbJT_EZeWLBRXx-3M9I_-6yv_hQXl2__3ixuyo172Qquba61sPQGmMFtFUHcgAziIqCZAbatrZMD0CF7TQbdGM5INYDF5Y1XaX5GTk_xO6D_7FgTGoao0bnYEa_RCV4zapW1jSTrw7kV3Coxtn6FECvtNpVjDedFKzJ1PYBKi-D06j9jHbM8_-E8iDo4GMMaNU-jBOEW8WoWptT-W_V2pxam8v8y-ODl2FC848-VpWB10cAogZnA8x6jH-5Kl8tpZD8HlkIosU</recordid><startdate>20091101</startdate><enddate>20091101</enddate><creator>Park, Seung Chol</creator><creator>Jung, Sung Won</creator><creator>Lee, Jea Whan</creator><creator>Rim, Joung Sik</creator><general>Liebert</general><general>Mary Ann Liebert, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20091101</creationdate><title>The Effects of Tolterodine Extended Release and Alfuzosin for the Treatment of Double-J Stent―Related Symptoms</title><author>Park, Seung Chol ; Jung, Sung Won ; Lee, Jea Whan ; Rim, Joung Sik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-3cfc4cbb6ddf7a628a9badb720a91da664f1cba07f8c1bc5f3aee4b37f1582c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Adrenergic alpha-Antagonists - administration & dosage</topic><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alfuzosin</topic><topic>Benzhydryl Compounds - administration & dosage</topic><topic>Benzhydryl Compounds - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cresols - administration & dosage</topic><topic>Cresols - therapeutic use</topic><topic>Delayed-Action Preparations</topic><topic>Demography</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Muscarinic Antagonists - administration & dosage</topic><topic>Muscarinic Antagonists - therapeutic use</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Phenylpropanolamine - administration & dosage</topic><topic>Phenylpropanolamine - therapeutic use</topic><topic>Postoperative Complications - drug therapy</topic><topic>Postoperative Complications - etiology</topic><topic>Quinazolines - administration & dosage</topic><topic>Quinazolines - therapeutic use</topic><topic>Stents - adverse effects</topic><topic>Surveys and Questionnaires</topic><topic>Tolterodine Tartrate</topic><topic>Urologic diseases</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Seung Chol</creatorcontrib><creatorcontrib>Jung, Sung Won</creatorcontrib><creatorcontrib>Lee, Jea Whan</creatorcontrib><creatorcontrib>Rim, Joung Sik</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of endourology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Seung Chol</au><au>Jung, Sung Won</au><au>Lee, Jea Whan</au><au>Rim, Joung Sik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effects of Tolterodine Extended Release and Alfuzosin for the Treatment of Double-J Stent―Related Symptoms</atitle><jtitle>Journal of endourology</jtitle><addtitle>J Endourol</addtitle><date>2009-11-01</date><risdate>2009</risdate><volume>23</volume><issue>11</issue><spage>1913</spage><epage>1917</epage><pages>1913-1917</pages><issn>0892-7790</issn><eissn>1557-900X</eissn><abstract>To evaluate the effects of tolterodine extended release (ER) and alfuzosin for the treatment of Double-J stent-related lower urinary tract symptoms.
Fifty-two patients (33 men and 19 women; mean age 52.0 years) who underwent insertion of a Double-J stent after urological surgery were prospectively randomized into three groups. Group 1 included 20 patients who received 10 mg of alfuzosin, once daily for 6 weeks; group 2 included 20 patients who received 4 mg of tolterodine ER, once daily for 6 weeks; group 3 included 12 patients who received a placebo for the same protocol. All patients completed a validated Ureteral Stent Symptom Questionnaire at 6 weeks after the stent placement.
The mean urinary symptom index was 22.1 in group 1, 22.1 in group 2, and 28.1 in the placebo group (p = 0.032). The mean pain scores were 8.2, 11.7, and 16.2, respectively (p = 0.020). There were no significant differences in urinary symptoms and pain between the alfuzosin and tolterodine ER groups. In addition, there was no significant difference in the general health, work performance, and sexual performance scores among the groups.
Tolterodine ER and alfuzosin improve stent-related urinary symptoms and body pain.</abstract><cop>Larchmont, NY</cop><pub>Liebert</pub><pmid>19814699</pmid><doi>10.1089/end.2009.0173</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0892-7790 |
| ispartof | Journal of endourology, 2009-11, Vol.23 (11), p.1913-1917 |
| issn | 0892-7790 1557-900X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734126940 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adrenergic alpha-Antagonists - administration & dosage Adrenergic alpha-Antagonists - therapeutic use Adult Aged Aged, 80 and over Alfuzosin Benzhydryl Compounds - administration & dosage Benzhydryl Compounds - therapeutic use Biological and medical sciences Cresols - administration & dosage Cresols - therapeutic use Delayed-Action Preparations Demography Dosage and administration Drug therapy Female Humans Male Medical sciences Middle Aged Muscarinic Antagonists - administration & dosage Muscarinic Antagonists - therapeutic use Nephrology. Urinary tract diseases Phenylpropanolamine - administration & dosage Phenylpropanolamine - therapeutic use Postoperative Complications - drug therapy Postoperative Complications - etiology Quinazolines - administration & dosage Quinazolines - therapeutic use Stents - adverse effects Surveys and Questionnaires Tolterodine Tartrate Urologic diseases Young Adult |
| title | The Effects of Tolterodine Extended Release and Alfuzosin for the Treatment of Double-J Stent―Related Symptoms |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T05%3A51%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effects%20of%20Tolterodine%20Extended%20Release%20and%20Alfuzosin%20for%20the%20Treatment%20of%20Double-J%20Stent%E2%80%95Related%20Symptoms&rft.jtitle=Journal%20of%20endourology&rft.au=Park,%20Seung%20Chol&rft.date=2009-11-01&rft.volume=23&rft.issue=11&rft.spage=1913&rft.epage=1917&rft.pages=1913-1917&rft.issn=0892-7790&rft.eissn=1557-900X&rft_id=info:doi/10.1089/end.2009.0173&rft_dat=%3Cgale_proqu%3EA213589715%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734126940&rft_id=info:pmid/19814699&rft_galeid=A213589715&rfr_iscdi=true |